In vitro and in vivo enhancement effect of glabridin on the antibacterial activity of colistin, against multidrug resistant Escherichia coli strains

Background: The increase in antimicrobial resistance leads to complications in treatments, prolonged hospitalization, and increased mortality. Glabridin (GLA) is a hydroxyisoflavan from Glycyrrhiza glabra L. that exhibits multiple pharmacological activities. Colistin (COL), a last-resort Antibiotic, is increasingly being used in clinic against Gram-negative bacteria. Previous reports have shown that GLA is able to sensitize first line Antibiotics such as norfloxacin and vancomycin on Staphylococcus aureus, implying that the use of GLA as an Antibiotic adjuvant is a promising strategy for addressing the issue of drug resistance. However, the Adjuvant effect on Other Antibiotics, especially COL, on Gram-negative bacteria such as Escherichia coli has not been studied.

Purpose: The objective of our study was to investigate the targets of GLA and the synergistic effect of GLA and COL in E. coli, and to provide further evidence for the use of GLA as an Antibiotic adjuvant to alleviate the problem of drug resistance.

Methods: We first investigated the interaction between GLA and enoyl-acyl carrier protein reductase, also called "FabI", through Enzyme inhibition assay, differential scanning fluorimetry, isothermal titration calorimetry and molecular docking assay. We tested the transmembrane capacity of GLA on its own and combined it with several Antibiotics. The antimicrobial activities of GLA and COL were evaluated against six different susceptible and resistant E. coli in vitro. Their interactions were analyzed using checkerboard assay, time-kill curve and CompuSyn software. A series of sensitivity tests was conducted in E. coli overexpressing the fabI gene. The development of COL resistance in the presence of GLA was tested. The antimicrobial efficacy of GLA and COL in a mouse model of urinary tract Infection was assessed. The anti-biofilm effects of GLA and COL were investigated.

Results: In this study, Enzyme kinetic analysis and thermal analysis provided evidence for the interaction between GLA and FabI in E. coli. GLA enhanced the antimicrobial effect of COL and synergistically suppressed six different susceptible and resistant E. coli with COL. Overexpression experiments showed that targeted inhibition of FabI was a key mechanism by which GLA synergistically enhanced COL activity. The combination of GLA and COL slowed the development of COL resistance in E. coli. Combined GLA and COL treatment significantly reduced Bacterial load and mitigated urinary tract injury in a mouse model of E. coli urinary tract Infection. Additionally, GLA + COL inhibited the formation and eradication of biofilms and the synthesis of curli.

Conclusion: Our findings indicate that GLA synergistically enhances antimicrobial activities of COL by targeting inhibition of FabI in E. coli. GLA is expected to continue to be developed as an Antibiotic adjuvant to address drug resistance issues.

Antimicrobial resistance; Colistin; E. coli; Enoyl-acyl carrier protein reductase; Glabridin.